^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CALR mutation

    i
    Entrez ID:
    811
    Related biomarkers:
    Others
    Apply
    Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP) (NCT06715267)
    Phase N/A
    University Hospital, Brest
    Recruiting
    Last update posted :
    12/04/2024
    Initiation :
    04/01/2023
    Primary completion :
    04/01/2038
    Completion :
    04/01/2038
    JAK2 • CALR
    |
    CALR mutation
    Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis (ALLO-BAT) (NCT04217356)
    Phase N/A
    University Health Network, Toronto
    Recruiting
    Last update posted :
    03/22/2024
    Initiation :
    08/05/2020
    Primary completion :
    08/05/2025
    Completion :
    02/05/2026
    TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR
    |
    TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation
    |
    Jakafi (ruxolitinib) • hydroxyurea
    Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm (NCT05025488)
    Phase 1
    Marina Kremyanskaya
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    04/04/2023
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    CALR
    |
    CALR mutation
    |
    Hiltonol (poly-ICLC)
    CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms (NCT03566446)
    Phase 1
    Inge Marie Svane
    Completed
    Last update posted :
    07/13/2023
    Initiation :
    06/20/2018
    Primary completion :
    02/20/2020
    Completion :
    04/30/2021
    CALR
    |
    CALR mutation
    Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia (FAST) (NCT02611973)
    Phase 3
    Assistance Publique - Hôpitaux de Paris
    Recruiting
    Last update posted :
    07/26/2017
    Initiation :
    03/10/2016
    Primary completion :
    11/01/2019
    Completion :
    11/01/2022
    JAK2 • CALR
    |
    JAK2 V617F • CALR mutation
    |
    hydroxyurea • aspirin